Triple agonist: difference between revisions
Diff·revision 11 → 12·20:21, 6 Mar 2025
Difference between revision 11 and revision 12 of Triple agonist. 2 lines changed; the page grew by 186 bytes.
| Revision 11 — 01:20, 16 Feb 2025 CiteBot (talk) bot: normalise citation format 3,242 bytes +95 | Revision 12 — 20:21, 6 Mar 2025 CouplingCillian (talk) unpipe a link that did not need piping 3,428 bytes +186 | ||
|---|---|---|---|
| 25 | The second is the design's predicted failure mode. At low total dose the glucagon component is not yet offset by sufficient GLP-1 agonism, so glycaemia worsens before it improves — which is why escalation schedules for these compounds are long.{{r|coskun2022}} | 25 | The second is the design's predicted failure mode. At low total dose the glucagon component is not yet offset by sufficient GLP-1 agonism, so glycaemia worsens before it improves — which is why escalation schedules for these compounds are long.{{r|coskun2022}} |
| 26 | 26 | ||
| + | 27 | Long-term consequences of sustained heart-rate elevation are the question phase 3 exists to answer, and no answer is available yet. See [[TRIUMPH trial programme]].{{r|jastreboff2023}} | |
| + | 28 | ||
| 27 | == References == | 29 | == References == |
| 28 | {{reflist}} | 30 | {{reflist}} |